A b s t r a c t
Immunologic abnormalities in patients with cirrhosis strongly correlate with severity of liver cirrhosis. The association between cirrhosis and human herpesvirus type 8 (HHV-8) infection is unclear. Plasma samples were obtained from 74 healthy control subjects and 59 patients with cirrhosis. The seropositive rates for HHV-8 antibodies in patients with cirrhosis
) were significantly higher than that in healthy control subjects (18/74 [24%] ; P
= .027), particularly in men (P = .027), patients with alcohol-related cirrhosis (P = .032), and patients with thrombocytopenia (P = .019) or Child-Pugh class C cirrhosis (P = .018) or both (P = .015), or hepatitis B virus (HBV) infection (P = .003). Antibody titers in seropositive patients also significantly exceeded those in healthy control subjects (P = .008). All subjects were negative for anti-HIV. In Taiwan, cirrhosis is associated with HHV-8 infection, particularly in men, patients with Child-Pugh class C cirrhosis and/ or thrombocytopenia, and patients with alcohol-or HBV-related cirrhosis.
Kaposi sarcoma (KS) commonly develops in patients with AIDS and sometimes in patients without AIDS with variable immunologic abnormalities after corticosteroid, cytotoxic, or immunosuppressive therapy for malignancies, tissue transplants, or autoimmune diseases. [1] [2] [3] To date, human herpesvirus type 8 (HHV-8) DNA has been found consistently in all types of KS. 4, 5 Immunologic disturbances with impairment of immune function associated with spontaneous bacterial peritonitis and a higher incidence of lymphoproliferative disorders and other malignancies have been documented in patients with cirrhosis. [6] [7] [8] Peripheral blood CD3 and CD4 T-lymphocyte reduction has been shown to strongly correlate with cirrhosis severity. 6, 9 In addition, T-helper-cell type 2 immune responses can inhibit efficient immune function by secreting several cytokines, including interleukin-10 and transforming growth factor-β1. Serum transforming growth factor-β1 levels have been shown to be higher in patients with cirrhosis vs healthy control subjects. 10 Despite the preceding findings, the prevalence of HHV-8 infection in patients with cirrhosis has not been previously described.
The objective of this study was to assess the prevalence of HHV-8 infection in patients with cirrhosis compared with the general population and previously described HIV-infected patients without KS.
Materials and Methods

Healthy Control Subjects and Study Group
After obtaining informed consent from all subjects, residual plasma samples were obtained from 74 healthy control subjects (37 men and 37 women) and 59 patients with cirrhosis (38 men and 21 women; 25 Child-Pugh class B and 34 class C) after they had undergone medical examinations. The healthy control subjects were selected from persons who received routine health examinations during the same period and had been proven to be free of cirrhosis and other major disease. The mean age of the healthy control subjects was 53 years (range, 28-86 years). The mean age of the patients with cirrhosis was 59 years (range, 27-82 years). All subjects were negative for anti-HIV antibody.
Cirrhosis was diagnosed based on biopsy or on the presence of clinical and laboratory features of portal hypertension (esophageal varices at endoscopy and/or collateral circulation at ultrasonography). Disease severity was assessed according to the Child-Pugh scoring system. 11 Subjects with alcoholrelated cirrhosis were defined as those who had consumed at least 80 g of alcohol daily for at least the past 5 years. Cirrhosis with positive serum hepatitis B virus surface antigen (HBsAg) was considered to be hepatitis B virus (HBV)-related; subjects with positive serum anti-hepatitis C virus (anti-HCV) antibody were considered to have HCV-related cirrhosis. Subjects with positive blood cultures were ineligible for participation. Data for subjects who died within 10 days after sample collection were excluded.
Patients with cirrhosis were composed of the following groups: HBV-related only (n = 12); HCV-related only (n = 25); alcohol-related only (n = 9); HBV-and HCV-related (n = 1); HBV-and alcohol-related (n = 6); HCV-and alcoholrelated (n = 3); and unknown cause (n = 3).
The study protocol was approved by the institutional review board of the Buddhist Dalin Tzu Chi General Hospital, Taiwan.
Sample Collection and Processing
Plasma samples were collected in sterile tubes and centrifuged immediately at 4°C to remove cells. Aliquots of the supernatants were stored frozen at -70°C until needed. The lymphocyte, monocyte, and platelet counts from peripheral blood were analyzed by an automated hematologic analyzer (XE-2100, Sysmex, Kobe, Japan) before plasma sample collection. Lymphopenia was defined as a total lymphocyte count of less than 1,000/µL (1.0 × 10 9 /L), 12 monocytosis as a total monocyte count of greater than 700/µL (0.7 × 10 9 /L; upper limit of reference range), and thrombocytopenia as a total platelet count of less than 150 × 10 3 /µL (150 × 10 9 /L). 13 
Immunofluorescence Assay for Detection of the HHV-8 Antibody
A commercially available immunofluorescence assay (IFA) kit (ABI, Columbia, MD) was used to detect HHV-8 IgG antibodies against the lytic antigens in plasma samples according to the manufacturer's instructions. This assay was based on HHV-8-infected body cavity lymphoma cell lines. Human plasma and various dilutions to be tested were brought into contact with fixed infected cells and examined microscopically using a fluorescence microscope. Samples that displayed fluorescence at a dilution of 1:40 were considered positive. Maximum HHV-8 antibody dilutions were determined by an end point immunofluorescence assay.
Chemiluminescence Immunoassay for HBsAg, Anti-HCV, and Anti-HIV Plasma samples were assayed for HBsAg, anti-HCV, anti-HIV-1, and anti-HIV-2 using the Vitros HBsAg, anti-HCV, and anti-HIV 1+2 reagent packs, respectively, with controls and calibrators (Ortho-Clinical Diagnostics, High Wycombe, England), and Vitros ECi immunodiagnostic system (Ortho-Clinical Diagnostics, Rochester, NY) according to the manufacturers' instructions.
Statistical Analyses
The χ 2 test was used for categorical variables and linear trend. Differences in means of continuous variables between 2 groups of patients were analyzed by the t test. Statistical significance was set at a P value of less than .05. Statistical analyses were performed using SPSS 12.0 for Windows (SPSS, Chicago, IL).
Results
Lymphocyte, Monocyte, and Platelet Counts
There were significant differences between the mean lymphocyte, monocyte, and platelet counts in healthy control subjects and patients with cirrhosis (P < .0001; t test) 
Seropositive Cases
Subjects with a positive IFA result were considered to be HHV-8 seropositive. Significantly more patients with cirrhosis (25/59 [42%]) were seropositive vs healthy control subjects (18/74 [24%]; P = .027; χ 2 ). The mean ages of seropositive healthy control subjects and patients with cirrhosis were 52 years (range, 30-78 years) and 59 years (range, 43-81 years), respectively. None of the seropositive subjects had received intravenous gamma globulins. Positive rates in different dilutions among healthy control subjects and patients with cirrhosis are shown in Table 1 .
Antibody Titers
Antibody titers in seropositive patients with cirrhosis were significantly higher than those in healthy control subjects (P = .008; t test; Table 1 ). Detailed positive results in maximal dilution and positive rates in various subgroups of patients with cirrhosis are shown in zTable 2z.
Seropositive Rates by Sex
The HHV-8 seropositive rate among male healthy control subjects was relatively less than in female healthy control subjects (22% [8/37] vs 27% [10/37]; P = .588; χ 2 ). The mean ages of the seropositive male and female healthy control subjects were 56 years (range, 39-78 years) and 49 years (range, 40-56 years), respectively. Seropositive rates in male patients with cirrhosis were relatively greater than in females overall † Including HBV-related only (n = 12) and HBV-and alcohol-related (n = 6). ‡ Including HCV-related only (n = 25) and HCV-and alcohol-related (n = 3). § Including alcohol-related only (n = 9), HBV-and alcohol-related (n = 6), and HCV-and alcohol-related (n = 3).
(45% [17/38] Table 2 ) was significantly greater than that in healthy control subjects (24% [18/74] ; P = .027; χ 2 ).
Seropositive Rates by Child-Pugh Class
Of the 18 subjects with HBV-related cirrhosis, 5 (28%) had Child-Pugh class B and 13 (72%) had class C disease. In subjects with HCV-related cirrhosis, Child-Pugh class B and class C each comprised 50% of patients. Of 18 patients with alcohol-related cirrhosis, 7 (39%) had Child-Pugh class B and 11 (61%) had class C disease.
The seropositive rate of HHV-8 antibody increased with the severity of cirrhosis. The rate observed in patients with Child-Pugh class B cirrhosis (36% [9/25] ) was less than that in patients with class C cirrhosis (47% [16/34] ); both were greater than the 24% observed in healthy control subjects (patients with Child-Pugh class B and C disease vs healthy control subjects, respectively; P = .257 and P = .018; χ 2 ; Table 2 ). In both sexes, the seropositive rates in patients with Child-Pugh class B cirrhosis were less than in patients with class C cirrhosis (40% [6/15] 
Seropositive Rates by Disease Etiology
In subjects with cirrhosis, 18 (31%) were positive for HBsAg, 28 (47%) were positive for anti-HCV, and 1 (2%) was positive for both ( Table 2 ). The seropositive rate in patients with HBV-related-only cirrhosis (58% [7/12] ) was greater than that for the entire test group (42% [25/59]), for subjects with HCV-related-only cirrhosis (32% [8/25] ), and for subjects with alcohol-related-only cirrhosis (44% [4/9]) (P = .311, P = .167, and P = .528, respectively; χ 2 ). In healthy control subjects, 7 subjects (9%) were positive for HBsAg and 2 (3%) were positive for anti-HCV.
The HHV-8 positive rates in all HBV-related (61% [11/18] ) and all alcohol-related (50% [9/18]) cases of cirrhosis were significantly greater than the rate in healthy control subjects (24% [18/74]; P = .003 and P = .032, respectively; χ 2 ). The HHV-8 positive rates in all HCV-related (32% [9/28]) were not significantly different from those in healthy control subjects (P = .424; χ 2 ). The comparison of seropositive rates of HHV-8 between patients with cirrhosis with different causes and healthy control subjects is shown in Table 2 .
Seropositivity and Lymphocyte, Monocyte, and Platelet Counts
There were no significant differences in mean lymphocyte or monocyte counts between seronegative and seropositive healthy control subjects and patients with cirrhosis or total seronegative and total seropositive subjects zTable 3z and zTable 4z. Among patients with cirrhosis with lymphopenia, 40% (14/35) were seropositive. Among patients with cirrhosis without lymphopenia, 46% (11/24) were seropositive (P = .656; χ 2 ). The 1 healthy control subject with lymphopenia was seronegative for HHV-8 IgG. The seropositive rates in patients with cirrhosis with and without monocytosis were 43% (6/14) and 42% (19/45), respectively. The difference in mean platelet counts between seronegative and seropositive healthy control subjects and patients with cirrhosis was not significant. There was a significant difference between total seropositive and seronegative subjects (P = .038; t test) zTable 5z. Seropositive rates in thrombocytopenic and nonthrombocytopenic subjects are shown in zTable 6z. The 1 healthy control subject with thrombocytopenia was seronegative for HHV-8 IgG. The seropositive rates in thrombocytopenic patients with cirrhosis (44% [23/52] ) and combined with Child-Pugh class C cirrhosis (48% [15/31] ) were significantly greater than the seropositive rate in healthy control subjects (24% [18/74]) (P = .019 and P = .015, respectively; χ 2 ) and in total nonthrombocytopenic subjects (25% [20/80] ; P = .021 and P = .017, respectively; χ 2 ). The rate in total thrombocytopenic subjects was also significantly greater than that in total nonthrombocytopenic subjects (P = .021; χ 2 ). Seropositivity was not associated with manifestations of HHV-8 infection.
Discussion
In our study, almost 50% of the patients with cirrhosis had HCV-related cirrhosis, suggesting that HCV is endemic in Chiayi County, located in southern Taiwan, a documented HBV-endemic country. 14 Inhibitions of T-lymphocyte and natural killer cell proliferations have been reported in HCV-infected patients. [15] [16] [17] In patients with alcohol-related liver disease and nonalcoholic hepatitis or cirrhosis, peripheral blood T-cell numbers have been shown to be significantly decreased when compared with counts in healthy control subjects. It has also been reported that mean B-cell counts in patients with alcohol-related liver disease are decreased compared with counts in healthy control subjects. 18 In our study, the mean lymphocyte count in patients with cirrhosis was markedly less than that in healthy control subjects (P < .0001; t test). Lymphopenia was noted in only 1 healthy control subject; however, it was common in patients with cirrhosis. The proportions of lymphopenia in patients with HBV-related, HCV-related, and alcohol-related cirrhosis were similar, indicating that it was independent of the underlying cirrhosis-related etiology. In addition, lymphopenia did not seem to be associated with seropositivity for HHV-8 IgG antibody.
In the present study, none of the healthy control subjects had monocytosis; however, it was present in patients with cirrhosis, particularly in patients with HCV-related cirrhosis. In patients with chronic HCV infection, monocytosis is likely to be associated with the impaired maturation and allostimulatory function of monocyte-derived dendritic cells. 19, 20 However, monocytosis was also present in patients with HBV-related and alcohol-related cirrhosis, but its presence did not correlate with the rate of seropositivity. To the best of our knowledge, this is the first report of the association of monocytosis with cirrhosis. In light of our results, additional studies to determine the relationship between monocytosis and cirrhosis are warranted. The HHV-8 seropositive rate among healthy control subjects in our study was comparable to that previously reported in the general population of Taiwan 21 ; however, the prevalence of HHV-8 infection in patients with cirrhosis was significantly greater than that in healthy control subjects. The antibody titers of the seropositive patients with cirrhosis also exceeded those in healthy control subjects.
Although the prevalence of HHV-8 infection in patients with cirrhosis was less than that reported in most patients with KS, [21] [22] [23] [24] it is higher than that previously reported in many HIV-infected patients without KS. [21] [22] [23] [24] [25] [26] The high seropositive rate for HHV-8 antibodies in patients with cirrhosis in our study suggests that many of these patients have, at one time, been infected with HHV-8, which may be associated with the impairment of cellular immunity described in the patients. 6, 7 In our study, the seropositive rate of HHV-8 antibody increased with the severity of cirrhosis. The rate in subjects with Child-Pugh class C cirrhosis was relatively greater than that in patients with class B disease. Similar results were found in both sexes. This finding may be associated with a progressive decrease in cellular immunity as the severity of cirrhosis increases. 6 In our study, the seropositive rates in patients with cirrhosis seemed to correlate with the underlying etiologies, as they were particularly high in patients with alcohol-related and HBV-related cirrhosis.
Functional abnormalities of dendritic cells, natural killer cells, memory CD4+ T cells, and CD8+ T cells, as well as inhibition of T-lymphocyte proliferation, have been found in patients with chronic HCV infection. [15] [16] [17] [27] [28] [29] [30] [31] [32] Cellular and humoral immunologic abnormalities have been described as contributing to the process of alcohol-related cirrhosis. 9 However, at least in our study, the seropositive rate of HHV-8 antibodies in patients with HCV-related and alcohol-related cirrhosis was not greater than in patients with HBV-related disease. On the contrary, the rate in patients with HBV-related cirrhosis was relatively greater than that in the entire test group and in patients with HCV-related or alcohol-related cirrhosis. It is interesting that the HHV-8 positive rate in patients with HCV-related cirrhosis was relatively less than that in total patients tested, although the difference was not significant.
Thrombocytopenia is common in patients with cirrhosis. It mainly results from overdestruction of platelets due to hypersplenism and indirectly correlates with the severity of portal hypertension present in cirrhosis. Thrombocytopenia was present in a high proportion of the patients with cirrhosis in our study.
The seropositive rate in patients with cirrhosis with thrombocytopenia, particularly in patients with Child-Pugh class C cirrhosis, was significantly greater than the rates in healthy control subjects and total nonthrombocytopenic subjects. Thrombocytopenia has been reported as a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high risk for hepatocellular carcinoma. 13, 33 The similarity between the rate of HHV-8 IgG seropositivity in patients with cirrhosis and patients with thrombocytopenia indirectly support this hypothesis.
KS is mainly found in elderly men. 3, 26 In our study, although the differences were not significant, the HHV-8 seropositive rate among healthy male control subjects was relatively less than in female control subjects; in subjects with cirrhosis, it was relatively greater in men vs women. There was a significant difference, however, in the seropositive rate in men with cirrhosis vs healthy control subjects.
Seropositivity did not seem to be associated with overt HHV-8-associated clinical manifestations in our study. Thus, cofactors that contribute to the development of KS and other HHV-8-associated diseases in HHV-8-seropositive individuals, other than being of male sex, ethnic origin, and being immunocompromised, are still elusive. Reactivation of cytomegalovirus in patients with cirrhosis has been documented. 34, 35 Further investigation is needed to determine if the high seropositive rate of HHV-8 IgG in patients with cirrhosis is associated with HHV-8 reactivation. However, in contrast with more than 90% of healthy control subjects seropositive for cytomegalovirus, 34 only 24% of the healthy control subjects in the present study were seropositive for HHV-8. Hence, the role of HHV-8 in patients with cirrhosis may be different from that of cytomegalovirus.
In our study, the seropositive rate of HHV-8 IgG antibody in patients with cirrhosis was significantly greater than that in healthy control subjects. Antibody titers in the positive patients also significantly exceeded titers in healthy control subjects, and the seropositive rate in patients with cirrhosis increased with the severity of cirrhosis. Our findings support the suggestion that cirrhosis is relatively highly associated with HHV-8 infection, particularly in male patients, patients with thrombocytopenia and/or Child-Pugh class C cirrhosis, and patients with alcoholism or HBV infection, at least in Taiwan. The relationship between HHV-8 infection and the disease course of the cirrhosis needs to be further explored.
